Format

Send to

Choose Destination
Br J Cancer. 2011 Nov 22;105(11):1693-6. doi: 10.1038/bjc.2011.398. Epub 2011 Oct 27.

Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer.

Author information

1
Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin-Kawahara-cho, Sakyo-ku, Kyoto, Japan. kanai@kuhp.kyoto-u.ac.jp

Abstract

BACKGROUND:

A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported.

METHODS:

Blood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated.

RESULTS:

Twenty-five patients (30%) demonstrated an average temporary drop of 20 mm Hg or more in systolic blood pressure. We classified these 25 patients as group A and the others as group B. Median time-to-treatment failure (TTF) was significantly longer in group A than in group B (291 vs 162 days; P=0.02). Furthermore, the proportion of patients who required intervention with antihypertensive drugs during bevacizumab treatment was significantly higher in group A than in group B (36% vs 4%; P<0.01).

CONCLUSION:

This study suggests that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacizumab treatment.

PMID:
22033274
PMCID:
PMC3242590
DOI:
10.1038/bjc.2011.398
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center